Changes in hepatitis C virus (HCV) viral load and interferon-α levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy

William A. Bower, David H. Culver, Delivette Castor, Yingfeng Wu, V. Nicole James, HaoQiang Zheng, Scott Hammer, Wendi L. Kuhnert, Ian T. Williams, Beth P. Bell, David Vlahov, Charlene S. Dezzutti

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Reports are mixed as to whether highly active antiretroviral therapy (HAART) increases liver transaminase levels or hepatitis C virus (HCV) titers in HIV/HCV-coinfected individuals. It is hypothesized that increases in HCV RNA titers may result from changes in endogenous interferon-α (IFN-α) production. METHODS: HIV/HCV-coinfected patients receiving HAART were tested at baseline, 1, 2, 3, 6, and 9 months for liver transaminase levels, HIV and HCV viral loads, and IFN-α. Linear regression analysis was used to determine the effect of HAART on liver transaminase levels, HCV viral load, and IFN-α. RESULTS: Initiating HAART did not increase liver transaminase levels in majority of cases. In patients (n = 30) with baseline HIV titer >10,000 copies/mL, HCV titers increased 0.69 log10 and IFN-α decreased -0.96 log10 during HAART, in association with a ≥0.5 log10 decrease in HIV titer. As HIV titers reached their nadir approximately 4 months after initiation of HAART, HCV titers remained 0.54 log10 and IFN-α -0.71 log10 above and below baseline levels, respectively. HCV titers and IFN-α levels did not change from baseline in patients with baseline HIV titer ≤10,000 copies/mL. CONCLUSIONS: Coinfected patients did not have evidence of hepatoxicity HAART. In patients with baseline HIV titer >10,000 copies/mL, suppression of HIV replication by HAART was associated with an increase in HCV titer and a decrease in endogenous IFN-α levels.

Original languageEnglish (US)
Pages (from-to)293-297
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume42
Issue number3
DOIs
StatePublished - Jul 2006
Externally publishedYes

Fingerprint

Highly Active Antiretroviral Therapy
Viral Load
Hepacivirus
Interferons
HIV
Liver
Transaminases
Linear Models
Regression Analysis
RNA

Keywords

  • Coinfection
  • HAART
  • Hepatitis C virus
  • Hepatotoxicity
  • HIV/AIDS
  • Interferon-α
  • Viral load

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Changes in hepatitis C virus (HCV) viral load and interferon-α levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy. / Bower, William A.; Culver, David H.; Castor, Delivette; Wu, Yingfeng; James, V. Nicole; Zheng, HaoQiang; Hammer, Scott; Kuhnert, Wendi L.; Williams, Ian T.; Bell, Beth P.; Vlahov, David; Dezzutti, Charlene S.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 42, No. 3, 07.2006, p. 293-297.

Research output: Contribution to journalArticle

Bower, WA, Culver, DH, Castor, D, Wu, Y, James, VN, Zheng, H, Hammer, S, Kuhnert, WL, Williams, IT, Bell, BP, Vlahov, D & Dezzutti, CS 2006, 'Changes in hepatitis C virus (HCV) viral load and interferon-α levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy', Journal of Acquired Immune Deficiency Syndromes, vol. 42, no. 3, pp. 293-297. https://doi.org/10.1097/01.qai.0000221689.77220.42
Bower, William A. ; Culver, David H. ; Castor, Delivette ; Wu, Yingfeng ; James, V. Nicole ; Zheng, HaoQiang ; Hammer, Scott ; Kuhnert, Wendi L. ; Williams, Ian T. ; Bell, Beth P. ; Vlahov, David ; Dezzutti, Charlene S. / Changes in hepatitis C virus (HCV) viral load and interferon-α levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy. In: Journal of Acquired Immune Deficiency Syndromes. 2006 ; Vol. 42, No. 3. pp. 293-297.
@article{3c710ca1dd70453ebb99c49d788dd4a1,
title = "Changes in hepatitis C virus (HCV) viral load and interferon-α levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy",
abstract = "BACKGROUND: Reports are mixed as to whether highly active antiretroviral therapy (HAART) increases liver transaminase levels or hepatitis C virus (HCV) titers in HIV/HCV-coinfected individuals. It is hypothesized that increases in HCV RNA titers may result from changes in endogenous interferon-α (IFN-α) production. METHODS: HIV/HCV-coinfected patients receiving HAART were tested at baseline, 1, 2, 3, 6, and 9 months for liver transaminase levels, HIV and HCV viral loads, and IFN-α. Linear regression analysis was used to determine the effect of HAART on liver transaminase levels, HCV viral load, and IFN-α. RESULTS: Initiating HAART did not increase liver transaminase levels in majority of cases. In patients (n = 30) with baseline HIV titer >10,000 copies/mL, HCV titers increased 0.69 log10 and IFN-α decreased -0.96 log10 during HAART, in association with a ≥0.5 log10 decrease in HIV titer. As HIV titers reached their nadir approximately 4 months after initiation of HAART, HCV titers remained 0.54 log10 and IFN-α -0.71 log10 above and below baseline levels, respectively. HCV titers and IFN-α levels did not change from baseline in patients with baseline HIV titer ≤10,000 copies/mL. CONCLUSIONS: Coinfected patients did not have evidence of hepatoxicity HAART. In patients with baseline HIV titer >10,000 copies/mL, suppression of HIV replication by HAART was associated with an increase in HCV titer and a decrease in endogenous IFN-α levels.",
keywords = "Coinfection, HAART, Hepatitis C virus, Hepatotoxicity, HIV/AIDS, Interferon-α, Viral load",
author = "Bower, {William A.} and Culver, {David H.} and Delivette Castor and Yingfeng Wu and James, {V. Nicole} and HaoQiang Zheng and Scott Hammer and Kuhnert, {Wendi L.} and Williams, {Ian T.} and Bell, {Beth P.} and David Vlahov and Dezzutti, {Charlene S.}",
year = "2006",
month = "7",
doi = "10.1097/01.qai.0000221689.77220.42",
language = "English (US)",
volume = "42",
pages = "293--297",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Changes in hepatitis C virus (HCV) viral load and interferon-α levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy

AU - Bower, William A.

AU - Culver, David H.

AU - Castor, Delivette

AU - Wu, Yingfeng

AU - James, V. Nicole

AU - Zheng, HaoQiang

AU - Hammer, Scott

AU - Kuhnert, Wendi L.

AU - Williams, Ian T.

AU - Bell, Beth P.

AU - Vlahov, David

AU - Dezzutti, Charlene S.

PY - 2006/7

Y1 - 2006/7

N2 - BACKGROUND: Reports are mixed as to whether highly active antiretroviral therapy (HAART) increases liver transaminase levels or hepatitis C virus (HCV) titers in HIV/HCV-coinfected individuals. It is hypothesized that increases in HCV RNA titers may result from changes in endogenous interferon-α (IFN-α) production. METHODS: HIV/HCV-coinfected patients receiving HAART were tested at baseline, 1, 2, 3, 6, and 9 months for liver transaminase levels, HIV and HCV viral loads, and IFN-α. Linear regression analysis was used to determine the effect of HAART on liver transaminase levels, HCV viral load, and IFN-α. RESULTS: Initiating HAART did not increase liver transaminase levels in majority of cases. In patients (n = 30) with baseline HIV titer >10,000 copies/mL, HCV titers increased 0.69 log10 and IFN-α decreased -0.96 log10 during HAART, in association with a ≥0.5 log10 decrease in HIV titer. As HIV titers reached their nadir approximately 4 months after initiation of HAART, HCV titers remained 0.54 log10 and IFN-α -0.71 log10 above and below baseline levels, respectively. HCV titers and IFN-α levels did not change from baseline in patients with baseline HIV titer ≤10,000 copies/mL. CONCLUSIONS: Coinfected patients did not have evidence of hepatoxicity HAART. In patients with baseline HIV titer >10,000 copies/mL, suppression of HIV replication by HAART was associated with an increase in HCV titer and a decrease in endogenous IFN-α levels.

AB - BACKGROUND: Reports are mixed as to whether highly active antiretroviral therapy (HAART) increases liver transaminase levels or hepatitis C virus (HCV) titers in HIV/HCV-coinfected individuals. It is hypothesized that increases in HCV RNA titers may result from changes in endogenous interferon-α (IFN-α) production. METHODS: HIV/HCV-coinfected patients receiving HAART were tested at baseline, 1, 2, 3, 6, and 9 months for liver transaminase levels, HIV and HCV viral loads, and IFN-α. Linear regression analysis was used to determine the effect of HAART on liver transaminase levels, HCV viral load, and IFN-α. RESULTS: Initiating HAART did not increase liver transaminase levels in majority of cases. In patients (n = 30) with baseline HIV titer >10,000 copies/mL, HCV titers increased 0.69 log10 and IFN-α decreased -0.96 log10 during HAART, in association with a ≥0.5 log10 decrease in HIV titer. As HIV titers reached their nadir approximately 4 months after initiation of HAART, HCV titers remained 0.54 log10 and IFN-α -0.71 log10 above and below baseline levels, respectively. HCV titers and IFN-α levels did not change from baseline in patients with baseline HIV titer ≤10,000 copies/mL. CONCLUSIONS: Coinfected patients did not have evidence of hepatoxicity HAART. In patients with baseline HIV titer >10,000 copies/mL, suppression of HIV replication by HAART was associated with an increase in HCV titer and a decrease in endogenous IFN-α levels.

KW - Coinfection

KW - HAART

KW - Hepatitis C virus

KW - Hepatotoxicity

KW - HIV/AIDS

KW - Interferon-α

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=33745893502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745893502&partnerID=8YFLogxK

U2 - 10.1097/01.qai.0000221689.77220.42

DO - 10.1097/01.qai.0000221689.77220.42

M3 - Article

C2 - 16763522

AN - SCOPUS:33745893502

VL - 42

SP - 293

EP - 297

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 3

ER -